Neovascularization May Slow Progression of Geographic Atrophy

Neovascularization, or new blood vessel growth, is a restorative function of the body that assists in healing. When it occurs in the retina, however, it can lead to vision loss. In age-related macular degeneration (AMD) the photoreceptor cells weaken over time. In about 10 to 15 percent of AMD patients, the inflammatory system sends new [Read More]

New Website Brings AMD Groups Together

AMD Central.org provides access to resources for patients and caregivers in one location  The American Macular Degeneration Foundation, BrightFocus Foundation, MD Support, Prevent Blindness and The SupportSight Foundation have launched AMD Central, an online resource that curates trusted information and tools from leading advocacy organizations to support the age-related macular degeneration (AMD) patient and caregiver community. [Read More]

Latest statistics on prevalence of blindness and low vision worldwide

The Vision Loss Expert Group (VLEG) has published new findings about four areas of interest to the blind and low vision community. The report provides timely updates on acuity measurement standards, prevalence of global cases, and prevalence of types of blindness and vision impairment. For those who are interested in statistics, here are summaries of [Read More]

Newest Sustained-Release Anti-VEGF Drug in Trials

EyePoint Pharmaceuticals, Inc. announced on January 28, 2021 that the first patient has been dosed in their Phase 1 clinical trial of EYP-1901.   EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration (wAMD). It is the newest of several sustained delivery drugs under study, this one promising to extend [Read More]